Group 1 - Halper Sadeh LLC is investigating potential violations of federal securities laws and breaches of fiduciary duties related to the sale of Olo Inc. to Thoma Bravo for $10.25 per share in cash [1] - Enzo Biochem, Inc. is being investigated for its sale to Battery Ventures for $0.70 per share in cash [2] - Streamline Health Solutions, Inc. is under investigation for its sale to MDaudit for $5.34 per share in cash [2] Group 2 - Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures, and other relief on behalf of shareholders [3] - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options [4] - The firm represents investors globally who have experienced securities fraud and corporate misconduct, recovering millions for defrauded investors [4]

Exhibit 99.1 Streamline Health® Reports Fiscal First Quarter 2025 Financial Results Atlanta, GA, June 16, 2025 (Globe Newswire) – Streamline Health Solutions, Inc. ("Streamline" or the "Company") (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the fiscal first quarter of 2025 which ended April 30, 2025. Fiscal First Quarter Financial Results Total revenue for the f ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to ____________ Commission File Number: 000-28132 STREAMLINE HEALTH SOLUTIONS, INC. (Exact name of registrant as specified in its c ...

Core Insights - Streamline Health Solutions reported a total revenue increase of approximately 12% to $4.8 million for the first quarter of fiscal 2025 compared to $4.3 million in the same period of fiscal 2024, driven by new SaaS contracts despite some client non-renewals [2][4] - SaaS revenue grew by 23% to $3.4 million, representing 70% of total revenue in Q1 2025, up from 63% in Q1 2024 [3] - The company experienced a reduced net loss of $1.6 million in Q1 2025, an improvement from a net loss of $2.7 million in Q1 2024, attributed to increased revenue and cost savings from strategic restructuring [4][5] - Streamline Health Solutions entered into a definitive merger agreement with MDaudit for an all-cash transaction valued at approximately $37.4 million, with a share price premium of 138% over the last trading day prior to the announcement [6] Financial Performance - Total revenue for Q1 2025 was $4.8 million, a 12% increase from $4.3 million in Q1 2024 [2] - SaaS revenue for Q1 2025 was $3.4 million, a 23% increase from $2.7 million in Q1 2024, making up 70% of total revenue [3] - Adjusted EBITDA improved to $0.2 million in Q1 2025 from a loss of $0.7 million in Q1 2024, reflecting the company's focus on SaaS revenue growth and cost savings [5][18] Balance Sheet and Cash Flow - As of April 30, 2025, cash and cash equivalents were $1.4 million, down from $2.2 million as of January 31, 2025 [4][16] - Total assets increased to $35.8 million as of April 30, 2025, compared to $35.6 million as of January 31, 2025 [16] - Total liabilities rose to $24.8 million as of April 30, 2025, from $23.3 million as of January 31, 2025 [16] Merger Agreement - The merger with MDaudit is expected to close in the third quarter of calendar year 2025, with MDaudit acquiring all outstanding shares of Streamline stock for $5.34 per share [6]

Core Points - Class Action Attorney Juan Monteverde's firm, Monteverde & Associates PC, is investigating Streamline Health Solutions, Inc. regarding its sale to MDaudit for $5.34 per share [1] - The firm has a successful track record in recovering millions for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report [1] Company Information - Monteverde & Associates PC is headquartered in the Empire State Building, New York City, and operates as a national class action securities firm [2] - The firm has a history of litigating and recovering money for shareholders, including cases that have reached the U.S. Supreme Court [2] Contact Information - Shareholders with concerns regarding Streamline Health Solutions can contact Juan Monteverde via email or telephone for additional information [3]

Core Viewpoint - MDaudit is set to acquire Streamline Health Solutions in a cash transaction valued at approximately $37.4 million, which includes debt, aiming to enhance financial performance and billing compliance in healthcare organizations [2][3]. Company Overview - MDaudit is a cloud-based platform focused on continuous risk monitoring, helping healthcare organizations minimize billing risks and maximize revenues [2][12]. - Streamline Health Solutions provides solutions that enable healthcare providers to improve financial performance and address revenue leakage [13]. Merger Details - The acquisition will involve MDaudit purchasing all outstanding shares of Streamline stock for $5.34 per share, representing a premium of 138% over Streamline's closing price on May 28, 2025 [3][7]. - The merger is expected to close in the third quarter of 2025, after which Streamline will become a wholly-owned subsidiary of MDaudit and its stock will no longer be listed on the Nasdaq [8]. Strategic Rationale - The merger aims to combine Streamline's pre-bill integrity solutions with MDaudit's billing compliance and revenue integrity platform, enhancing the ability to unify data silos and improve revenue cycle management [4][5]. - Both companies share a vision of improving financial stability for healthcare organizations, which is increasingly important given the financial pressures faced by health systems [5][6]. Financial Implications - The combined entity will support healthcare organizations with an aggregate Net Patient Revenue exceeding $300 billion, providing enhanced visibility and actionable insights across the revenue cycle [1][4].

Streamline Health Solutions (STRM) Q4 2025 Earnings Call May 02, 2025 09:00 AM ET Company Participants Jacob Goldberger - VP - FinanceBen Stilwill - President & CEOBryant Reeves - Chief Financial OfficerNeil Cataldi - Principal Operator As a reminder, this conference is being recorded. It is now my pleasure to introduce Jacob Goldberger, Vice President of Finance. Thank you. You may begin. Jacob Goldberger Thank you for joining us for the corporate update and financial results review of Streamline Health So ...

Financial Performance - Total revenues for fiscal year 2024 decreased to $17,901,000, down 20.5% from $22,596,000 in fiscal year 2023[246] - Net loss for fiscal year 2024 was $10,159,000, an improvement from a net loss of $18,697,000 in fiscal year 2023, representing a 45.4% reduction in losses[246] - Operating expenses for fiscal year 2024 totaled $25,930,000, down 38.5% from $42,243,000 in fiscal year 2023[246] - The company reported a basic and diluted earnings per share of $(2.53) for fiscal year 2024, compared to $(4.96) for fiscal year 2023[246] - Operating loss for fiscal year 2024 was $8.03 million, compared to an operating loss of $19.65 million in fiscal year 2023, indicating an improvement[263] - The Company recorded a net loss of $10.16 million for fiscal year 2024, compared to a net loss of $18.7 million in fiscal year 2023[263] Assets and Liabilities - Total assets decreased from $41,735,000 in 2024 to $35,579,000 in 2025, representing a decline of approximately 14.4%[242] - Cash and cash equivalents decreased from $3,190,000 in 2024 to $2,183,000 in 2025, a reduction of about 31.5%[242] - Accounts receivable decreased from $4,237,000 in 2024 to $1,585,000 in 2025, a decline of approximately 62.6%[242] - Total current liabilities increased to $23,062,000 in January 2025, up from $13,682,000 in January 2024[244] - Total stockholders' equity decreased to $12,277,000 in January 2025, down from $18,814,000 in January 2024[244] - The Company has approximately $13.1 million in total outstanding debt as of January 31, 2025, classified as a current liability[261] Cash Flow and Financing - The Company anticipates the need for additional liquidity in the next twelve months due to insufficient cash flow from operations[260] - The Company recorded a net cash used in operating activities of $1,514,000 for fiscal year 2024, an improvement from $2,215,000 in fiscal year 2023[251] - The Company recorded a term loan principal balance of $7,500,000 as of January 31, 2025, down from $9,000,000 in the previous year, representing a decrease of approximately 16.67%[360] - The Company has a revolving line of credit with an outstanding balance of $1,000,000 as of January 31, 2025, compared to $1,500,000 in the previous year, indicating a reduction of 33.33%[364] - The Company incurred $200,000 in financing costs related to the Loan Agreement, which are being amortized over the term of the loan[363] Research and Development - Research and development expenses for fiscal year 2024 were $4,629,000, a decrease of 18.8% from $5,704,000 in fiscal year 2023[246] - The Company recorded an impairment of long-lived assets amounting to $963,000 in fiscal year 2023[281] - Capitalized software development costs for internal-use software amounted to $4,850,000 and $5,511,000 as of January 31, 2025 and 2024, respectively[283] Impairment and Valuation - The Company recorded a goodwill impairment of $9,813,000 for fiscal 2023[328] - The Company identified indicators of impairment due to a legacy client not renewing its contract and initiated impairment testing[387][392] - The Company has established a valuation allowance for deferred tax assets when it is more likely than not that some or all of the deferred tax assets will not be realized[338] Tax Positions - The Company recorded a reserve for uncertain tax positions of $331,000 as of January 31, 2025, down from $340,000 in 2024[404] - The federal tax benefit at the statutory rate for 2024 is $2,134,000, compared to $3,887,000 in 2023, indicating a decrease of approximately 45%[400] - The total deferred tax assets increased to $21,670,000 in 2025 from $19,651,000 in 2024, primarily due to changes in allowances and deferred revenue[400] Strategic Restructuring - The company executed a Strategic Restructuring on October 16, 2023, leading to a reduction of 26 employees, approximately 24% of its workforce, incurring one-time restructuring costs of approximately $759,000[344] - The company has recognized all expenses associated with the Strategic Restructuring as of the end of fiscal 2023, including severance and professional fees[344] Revenue Recognition - The Company utilizes the portfolio approach for revenue recognition, applying the revenue model to a portfolio of contracts with similar characteristics[304] - Revenue recognized over time was $17,617,000 in fiscal year 2024, down from $22,358,000 in fiscal year 2023, indicating a decline of approximately 21%[311] - Deferred revenue as of January 31, 2025, was $28,899,000, with an expectation to recognize approximately 47% over the next 12 months[312]

Streamline Health Solutions (STRM) Q4 2025 Earnings Call May 02, 2025 09:00 AM ET Speaker0 As a reminder, this conference is being recorded. It is now my pleasure to introduce Jacob Goldberger, Vice President of Finance. Thank you. You may begin. Speaker1 Thank you for joining us for the corporate update and financial results review of Streamline Health Solutions for the twelve and three months ended 01/31/2025. As the conference call operator indicated, my name is Jacob Goldberger. Joining me on the call t ...

[Financial Performance Overview](index=1&type=section&id=Financial%20Performance%20Overview) This section provides an overview of the company's financial performance, including management's strategic insights, detailed GAAP and non-GAAP results for fiscal year 2024, and future business outlook [Management Commentary](index=1&type=section&id=Management%20Commentary) Management highlights over $210 million in annualized client financial impact and focuses on targeted innovation for fiscal 2025, including new denial prevention functionality - The company's solutions are delivering an annualized financial impact of more than **$210 million** to its clients[2](index=2&type=chunk) - Fiscal 2025 will focus on targeted innovation, highlighted by the new denial prevention functionality within the eValuator solution, designed to help clients prevent denials in real-time[2](index=2&type=chunk) [Fiscal Fourth Quarter and Full Year 2024 GAAP Financial Results](index=1&type=section&id=Fiscal%20Fourth%20Quarter%20and%20Full%20Year%202024%20GAAP%20Financial%20Results) Fiscal 2024 GAAP results show total revenue decreased to $17.9 million, while net loss significantly improved to ($10.2 million) due to the absence of prior year impairment charges Fiscal Year Revenue Performance (GAAP) | Category | Fiscal Year 2024 | Fiscal Year 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $17.9 million | $22.6 million | -20.8% | | SaaS Revenue | $11.8 million | $14.1 million | -16.3% | Quarterly Revenue Performance (GAAP) | Category | Q4 2024 | Q4 2023 | Change | | :--- | :--- | :--- | :--- | | Total Revenue | $4.7 million | $5.4 million | -13.0% | | SaaS Revenue | $3.1 million | $3.4 million | -8.8% | Net Loss Performance (GAAP) | Period | Net Loss 2024 | Net Loss 2023 | | :--- | :--- | :--- | | Fiscal Year | ($10.2 million) | ($18.7 million) | | Fourth Quarter | ($2.1 million) | ($1.4 million) | - The improvement in the full-year net loss was primarily the result of **$10.8 million** of non-cash impairment charges incurred in fiscal 2023 that did not recur in fiscal 2024[5](index=5&type=chunk) - As of January 31, 2025, cash and cash equivalents were **$2.2 million**, down from **$3.2 million** a year prior. The outstanding balance on the revolving credit facility was reduced to **$1.0 million** from **$1.5 million**[6](index=6&type=chunk) [Fiscal Fourth Quarter and Full Year 2024 Non-GAAP Financial Results](index=2&type=section&id=Fiscal%20Fourth%20Quarter%20and%20Full%20Year%202024%20Non-GAAP%20Financial%20Results) Fiscal 2024 Non-GAAP results show Adjusted EBITDA improved to a ($1.3 million) loss, while Booked SaaS ACV decreased to $14.0 million but is projected to recover Adjusted EBITDA Performance (Non-GAAP) | Period | Adjusted EBITDA 2024 | Adjusted EBITDA 2023 | | :--- | :--- | :--- | | Fiscal Year | ($1.3 million) | ($1.4 million) | | Fourth Quarter | $35,000 | $0.4 million | Booked SaaS Annual Contract Value (ACV) | Date | Total Booked SaaS ACV | Implemented ACV | Unimplemented ACV | | :--- | :--- | :--- | :--- | | Jan 31, 2024 | $15.0 million | N/A | N/A | | Jan 31, 2025 | $14.0 million | $12.3 million | $1.7 million | | Apr 30, 2025 (Expected) | $14.6 million | $13.1 million | $1.5 million | - The decrease in booked SaaS ACV was largely due to previously reported client non-renewals, which was partially offset by **$3.5 million** of new bookings during fiscal year 2025[8](index=8&type=chunk) [Business Outlook](index=2&type=section&id=Business%20Outlook) The company expects to achieve a positive Adjusted EBITDA run rate in the first half of fiscal 2025 but refrains from specific bookings guidance due to timing unpredictability - The company reiterated its expectation to achieve an adjusted EBITDA positive run rate during the first half of fiscal 2025[10](index=10&type=chunk) - Due to continued unpredictability in the timing of closing new contracts, the Company has not provided more specific guidance related to the timing of bookings[10](index=10&type=chunk) [Consolidated Financial Statements](index=5&type=section&id=Consolidated%20Financial%20Statements) This section presents the company's consolidated financial statements, including detailed statements of operations, balance sheets, and cash flows for the reported periods [Consolidated Statements of Operations](index=5&type=section&id=Consolidated%20Statements%20of%20Operations) Fiscal year 2024 statements of operations show total revenues decreased to $17.9 million, while operating expenses significantly declined, leading to a reduced net loss of ($10.2 million) Fiscal Year 2024 vs 2023 Statement of Operations Highlights | Metric | Fiscal Year 2024 | Fiscal Year 2023 | | :--- | :--- | :--- | | Total Revenues | $17,901,000 | $22,596,000 | | Total Operating Expenses | $25,930,000 | $42,243,000 | | Impairment Charges | $0 | $10,776,000 | | Operating Loss | ($8,029,000) | ($19,647,000) | | Net Loss | ($10,159,000) | ($18,697,000) | | Basic and Diluted EPS | ($2.53) | ($4.96) | [Consolidated Balance Sheets](index=6&type=section&id=Consolidated%20Balance%20Sheets) As of January 31, 2025, total assets decreased to $35.6 million, primarily due to lower cash and receivables, resulting in a decline in total stockholders' equity to $12.3 million Balance Sheet Highlights (As of Jan 31) | Metric | 2025 | 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $2,183,000 | $3,190,000 | | Total Current Assets | $5,777,000 | $8,836,000 | | Total Assets | $35,579,000 | $41,735,000 | | Total Current Liabilities | $23,062,000 | $13,682,000 | | Total Liabilities | $23,302,000 | $22,921,000 | | Total Stockholders' Equity | $12,277,000 | $18,814,000 | [Consolidated Statements of Cash Flows](index=7&type=section&id=Consolidated%20Statements%20of%20Cash%20Flows) Fiscal year 2024 cash flow statements show improved net cash used in operating activities at ($1.5 million), with a net decrease in cash and cash equivalents of ($1.0 million) for the period Cash Flow Summary (Fiscal Year) | Cash Flow Activity | 2024 | 2023 | | :--- | :--- | :--- | | Net cash used in operating activities | ($1,514,000) | ($2,215,000) | | Net cash used in investing activities | ($858,000) | ($1,621,000) | | Net cash provided by financing activities | $1,365,000 | $428,000 | | **Net decrease in cash** | **($1,007,000)** | **($3,408,000)** | | Cash at end of period | $2,183,000 | $3,190,000 | [Supplemental Information](index=2&type=section&id=Supplemental%20Information) This section provides supplemental financial data, including the reconciliation of GAAP net loss to non-GAAP Adjusted EBITDA, and details for the upcoming conference call [Reconciliation of Net Loss to Non-GAAP Adjusted EBITDA](index=8&type=section&id=Reconciliation%20of%20Net%20Loss%20to%20Non-GAAP%20Adjusted%20EBITDA) This section reconciles the GAAP net loss to non-GAAP Adjusted EBITDA, showing an Adjusted EBITDA loss of ($1.3 million) for fiscal year 2024 after various adjustments Reconciliation of Net Loss to Adjusted EBITDA (Fiscal Year) | (in thousands) | 2024 | 2023 | | :--- | :--- | :--- | | Net loss | $(10,159) | $(18,697) | | Plus: Interest, Taxes, D&A | $6,357 | $5,254 | | Plus: Share-based compensation | $1,964 | $2,102 | | Plus: Impairment charges | $0 | $10,776 | | Other adjustments | $542 | $(821) | | **Adjusted EBITDA** | **$(1,296)** | **$(1,386)** | - Adjusted EBITDA is a non-GAAP measure defined as net earnings (loss) adjusted for interest, taxes, depreciation, amortization, share-based compensation, and other significant non-recurring or transactional expenses[15](index=15&type=chunk) [Conference Call Information](index=2&type=section&id=Conference%20Call%20Information) Details for the upcoming conference call on May 2, 2025, at 9:00 AM ET are provided, including access methods and replay availability - A conference call will be held on Friday, May 2, 2025, at **9:00 AM ET**[11](index=11&type=chunk) - A replay of the call will be available by phone until May 9, 2025, and an online replay will be available for six months in the Investor Relations section of the company's website[12](index=12&type=chunk)